Guerrero LCL

Idioma: Español
Referencias bibliográficas: 29
Paginas: 335-339
Archivo PDF: 119.43 Kb.

RESUMEN

La fibrosis sistémica nefrógena fue antecedida por la dermopatía fibrosante nefrógena, trastorno idiopático que se observó en pacientes con enfermedad renal, generalmente en hemodíalisis, con edad promedio de 40 a 50 años, se asoció a trastornos de la coagulación y cirugías. Los hallazgos dermatológicos consisten en engrosamiento e induración de la piel de aparición distal en tobillos, muslos, luego brazos y parte inferior de abdomen; respeta la cara. La biopsia de piel muestra haces de colágeno engrosados, deposición de mucina y proliferación de fibroblastos y fibras elásticas. Al reconocerse lesiones en pulmones, hígado, músculos y corazón pasó a ser un trastorno sístémico y cambió de nombre a fibrosis sistémica nefrógena, se ha relacionando con la exposición al gadolinio, medio de contraste usado en los estudios hechos con resonancia magnética . Se han identificado factores de riesgo que serán discutidos. No existe un tratamiento aceptado. En Europa se ha usado pentoxifilina por su efecto antifibrótico. Experimentalmente se ha usado fotoféresis. Es fundamental la prevención a través la educación e información al médico referente y al paciente sobre la posibilidad de esta complicación.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ayers R, Chandler J, Cowper Shawn, High W, Zito G. Gadoliniun is detectable within the tissue of patients with nephrogenic systemic fibrosis. JAAD 2007:56: 21-26

2. Bousquet JC Physico-chemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiology 1992;27 (Suppl):S2-S6).

3. Caravan P, Ellison JJ, Mc Murry TJ, Lauffer RB. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99:2293-2352

4. Collidge TA, Thomson PC, Mark PB, Traynor JP, Morris STW, Simpson K. Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Sudy of a Renal Replacement Therapy Cohort. Radiology: 2007; 245-1: 168-175.

5. Cowper SE, Robin HS, Steimberg SM. Su LD, Gupta S, Le Boit PE. Scleromyxedemalike cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1001

6. Cowper SE. Nephrogenic fibrosing dermopathy. The International Center for Nephrogenic Fibrosing Dermopathy Research.(ICN-FDR) (http://www.icnfdr.org) Published 2001. Updated January 13,2007.

7. Daram SR, Cortese CM, Bastani B Nephrogenic fibrosing dermopathy/Nephrogenic systemic fibrosis: report of a new case with literature review Am J Kidney Dis 2005;46:754-759

8. Gilliet M, Cozzio A, Burg G, Nestle FO. Susccesful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis Br J Dermatol 2005; 152: 531-536

9. Grobner T. Gadolinium- a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108

10. High WA, Ayers FA, Chandler J, Zito G, Cowper SE . Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol (JAAD) 2007;56:21-26

11. Issa N, Peggio E, Fatica R, Patel R, Ruggieri PM, Heyka RJ. Nephrogenic systemic fibrosis and its association with gadolinium exposure durng MRI. Cleve Clin J Med. 2008; 75:95-111

12. Jackson GE, Wynchank S, Wondenberg M. Gadolinium(III) complex equilibria: The implications for Gd(III) MRI contrast agents Mag Reson Med 1990;16:57-66

13. Kallen A, Jhung M, Cheng S, Hess T, Turabelidze G, Abramova L, et al. Gadolinium-Containing Magnetic Resonance Imaging Contrast and Nephrogenic Systemic Fibrosis: A case-Control Study. American Journal of Kidney Diseasses. 2008: 51: 966-975

14. Kay J. Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seen. Cleve Clin J Med 2008; 75:112-117

15. LeBoit PE: What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139:928-930

16. Marckmann P, Skov L, Rossen K, Dupont A. et al Nephrogenic systemic fibrosis: Suspected causative rol of gadodiamide used for contrast-enhanced Magnetic Resonance Imaging. J Am Soc Nephrol 2006;17:2359-2362

17. Oksendal AN. Hals PA. Biodistribution and toxicity of MR imaging contrast media J Magn Reson Imaging 1993;3:157-165

18. Penfield JG, Reilly RF Jr What nephrologists need to know about gadolinium Nature Clinical Practice 2007;3:654-668

19. Saab G, Abu-Alfa A Nephrogenic systemic fibrosis- implications for nephrologists Eur J Radiol 2008; 66:208-212

20. Sadowski EA, Bennett LK, Chan Mr, Wentland AL, Garret AL. Garrett RW Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology2007;243:148-157

21. Swaminathan S, Ahmed I, McCarthy JT, Albright RC et al Nephrogenic Fibrosing Dermopathy and high-dose erythropoietin therapy

22. Swartz RD, Crofford LJ, Phan SH,et al: Nephrogenic fibrosing dermopathy, a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114:563-572

23. Thomsen HS, Marckman P. Extracellular Gd-Ca: Difference in prevalence of NSF Eur J Radiol 2008;66:180-183

24. Ting WW, Stone Ms, Madison KC. Nephrogenic fibrosing dermopathy with systemic involvement Arch Dermatol 2003;139: 903-906.

25. Todd DJ. Nephrogenic systemic fibrosis: What nephrologists need to know. Nephrology Rounds 2007;5: número 6 (June/July). www.nephrologyrounds.org

26. Tombach B, Bremer C,Reimer P, Matzkies F et al Using highly concentrated Gadobutrol as an MR contrast agent in patients also requiring hemodialysissafety and disabiblity Am J Roentgen (AJR) 2002;178:105-109

27. Tweedle MF, Physico-chemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiology 1992;27 (Suppl):S2-S6).

28. Vorobiov M, Basok A, Tovbin D, Shnaider A, et al Iron-mobilization properties of the gadolinium-DTPA complex: clinical and experimental observations Neprol Dial Transplant 2003;18:884-887

29. Wiginton CD, Kelly B, Oto A, Jesse M, Ariatumuno P et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue AJR Am J Roentgenol 2008;190:1060-1068